MRI-detected bone marrow changes within 3 weeks after initiation of high-dose corticosteroid therapy: a possible change preceding the subsequent appearance of low-intensity band in femoral head osteonecrosis

2015 ◽  
Vol 35 (11) ◽  
pp. 1909-1912 ◽  
Author(s):  
Yusuke Kubo ◽  
Takuaki Yamamoto ◽  
Goro Motomura ◽  
Nobuaki Tsukamoto ◽  
Kazuyuki Karasuyama ◽  
...  
2000 ◽  
Vol 5 (4) ◽  
pp. 374-379 ◽  
Author(s):  
Kazuhiro Oinuma ◽  
Yoshitada Harada ◽  
Yasushi Nawata ◽  
Katsuhiko Takabayashi ◽  
Isao Abe ◽  
...  

2018 ◽  
Vol 45 (5) ◽  
pp. 592-595 ◽  
Author(s):  
Kota Tachibana ◽  
Toshihisa Hamada ◽  
Hiroki Tsuchiya ◽  
Takashi Shibata ◽  
Kazuyasu Fujii ◽  
...  

1996 ◽  
Vol 1 (1) ◽  
pp. 50-57 ◽  
Author(s):  
Robert S. Lester

Background: Systemic corticosteroids, a mainstay of treatment for severe dermatosis, are associated with systemic complications. Adverse effects of corticosteroids to bone represent a significant adverse effect that, is poorly understood and poorly managed. Objectives: The purpose of this article is to educate dermatologists to the current understanding of the pathogenesis, diagnosis, and treatment options available for bone complications of corticosteroids. Results: Virtually all patients chronically exposed to high-dose corticosteroid therapy lose bone mass and are at risk for osteoporotic fractures. In addition, osteonecrosis is an unpredictable complication of corticosteroid therapy that may occur with even low-dose corticosteroids. Conclusion: Optimal risk management of corticosteroid therapy includes understanding the risk factors associated with bone complications and improving communication with patients.


1992 ◽  
Vol 88 (1) ◽  
pp. 32-36 ◽  
Author(s):  
Yasushi Inoue ◽  
Atsushi Matsubara ◽  
Shigeru Okuya ◽  
Koichiro Okafuji ◽  
Kohei Kaku ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document